<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Dermaut, B.</title>
    <link>http://repub.eur.nl/res/aut/6937/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-based sample (Article)</title>
      <link>http://repub.eur.nl/res/pub/8490/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>We obtained conclusive linkage of Alzheimer disease (AD) with a candidate region of 19.7 cM at 7q36 in an extended multiplex family, family 1270, ascertained in a population-based study of early-onset AD in the northern Netherlands. Single-nucleotide polymorphism and haplotype association analyses of a Dutch patient-control sample further supported the linkage at 7q36. In addition, we identified a shared haplotype at 7q36 between family 1270 and three of six multiplex AD-affected families from the same geographical region, which is indicative of a founder effect and defines a priority region of 9.3 cM. Mutation analysis of coding exons of 29 candidate genes identified one linked synonymous mutation, g.38030G--&gt;C in exon 10, that affected codon 626 of the PAX transactivation domain interacting protein gene (PAXIP1). It remains to be determined whether PAXIP1 has a functional role in the expression of AD in family 1270 or whether another mutation at this locus explains the observed linkage and sharing. Together, our linkage data from the informative family 1270 and the association data in the population-based early-onset AD patient-control sample strongly support the identification of a novel AD locus at 7q36 and re-emphasize the genetic heterogeneity of AD.</description>
    </item> <item>
      <title>Polymorphisms in the prion protein gene and in the doppel gene increase susceptibility for Creutzfeldt-Jakob disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5883/</link>
      <pubDate>2004-05-01T00:00:00Z</pubDate>
      <description>The prion protein gene (PRNP) plays a central role in the origin of Creutzfeldt-Jakob disease (CJD), but there is growing interest in other polymorphisms that may be involved in CJD. Polymorphisms upstream of PRNP that may modulate the prion protein production as well as polymorphisms in the prion-like doppel gene (PRND) have been studied, with inconsistent findings. We investigated the role of a single-nucleotide polymorphism (SNP 1368) located upstream of PRNP and three polymorphisms in PRND (T26M, P56L and T174M) in CJD. The study included a population-based sample of 52 patients with sporadic CJD and 250 controls. We analysed our data as single markers and haplotypes. Further, we conducted a meta-analysis on PRND T174M comparing the data of the four studies conducted to date. For SNP 1368 and PRNP M129V, we found significant evidence for linkage disequilibrium. No evidence was found for a relation of SNP 1368 to CJD independent of PRNP M129V. We further found a significant increased prevalence of M homozygotes at PRND T174M among sporadic CJD patients, when adjusting the analyses for the other genotypes. In the haplotype analyses, the association was strongest for persons homozygous for PRNP 129M and PRND 174M (odds ratio 4.35, 95% confidence interval 1.05-8.09; P=0.04). The meta-analysis on the PRND T174M polymorphism did not show a consistent effect across studies, raising the question as to whether PRND 174M is causally related to CJD, or whether the PRND allele is in linkage disequilibrium with another polymorphism related to CJD.</description>
    </item> <item>
      <title>Early cognitive decline is associated with prion protein codon 129 polymorphism (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/5865/</link>
      <pubDate>2003-08-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample (Article)</title>
      <link>http://repub.eur.nl/res/pub/8503/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Nicastrin regulates gamma-secretase cleavage of the amyloid precursor protein by forming complexes with presenilins, in which most mutations causing familial early-onset Alzheimer disease (EOAD) have been found. The gene encoding nicastrin (NCSTN) maps to 1q23, a region that has been linked and associated with late-onset Alzheimer disease (LOAD) in various genome screens. In 78 familial EOAD cases, we found 14 NCSTN single-nucleotide polymorphisms (SNPs): 10 intronic SNPs, 3 silent mutations, and 1 missense mutation (N417Y). N417Y is unlikely to be pathogenic, since it did not alter amyloid beta secretion in an in vitro assay and its frequency was similar in case and control subjects. However, SNP haplotype estimation in two population-based series of Dutch patients with EOAD (n=116) and LOAD (n=240) indicated that the frequency of one SNP haplotype (HapB) was higher in the group with familial EOAD (7%), compared with the LOAD group (3%) and control group (3%). In patients with familial EOAD without the APOE epsilon4 allele, the HapB frequency further increased, to 14%, resulting in a fourfold increased risk (odds ratio = 4.1; 95% confidence interval 1.2-13.3; P=.01). These results are compatible with an important role of gamma-secretase dysfunction in the etiology of familial EOAD.</description>
    </item> <item>
      <title>Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5851/</link>
      <pubDate>2001-11-02T00:00:00Z</pubDate>
      <description>The beta-site of beta-amyloid precursor protein cleaving enzyme (BACE) cleaves the beta-amyloid (Abeta) precursor protein at the N-terminal end of Abeta, allowing for the production of Abeta by C-terminal gamma-secretase cleavage. We hypothesized that over-activity of BACE might lead to the overproduction of Abeta, hence causing Alzheimer's disease (AD). Molecular genetic analyses of BACE in 9 autosomal dominant AD families and a population-based sample of 101 presenile AD cases did not identify genetic linkage, pathogenic mutations or genetic association with BACE, suggesting that BACE is not genetically involved in the etiology of AD</description>
    </item> <item>
      <title>Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-jakob Disease phenotype (Article)</title>
      <link>http://repub.eur.nl/res/pub/5876/</link>
      <pubDate>2001-11-02T00:00:00Z</pubDate>
      <description>We investigated the risk associated with the codon 129 polymorphism in the prion protein gene (PRNP) and apolipoprotein E gene (APOE) isoforms for development of Creutzfeldt-Jakob disease (CJD) (n=126) and the possible influences on the disease pathology and its most important clinical characteristics. The PRNP M129V (PRNP129) polymorphism was determined using both DNA extracted from formalin fixed and paraffin embedded brain tissue (n=59) and leukocyte extracted DNA (n=67). In the latter group also the PRNP open reading frame and the APOE genotype were analysed and compared to a neurologically unaffected, age and sex matched control group (n=79). We found that methionine homozygosity of the PRNP129 increases the risk for developing CJD. PRNP129 also influenced the prion accumulation patterns in brain. The APOE 4 allele was an independent risk factor for developing CJD. We further observed a significant dose dependent APOE 4 effect on the number and type of amyloid-beta plaques in the brain of CJD patients.</description>
    </item> <item>
      <title>Variable expression of presenilin 1 is not a major determinant of risk for late-onset Alzheimer's Disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5852/</link>
      <pubDate>2001-11-01T00:00:00Z</pubDate>
      <description>We have previously reported a significant association between early-onset Alzheimer's disease (EOAD) and an allele in the promoter of presenilin 1 (PSEN1) significantly decreasing PSEN1 expression in vitro. For late-onset Alzheimer's disease (LOAD), numerous studies have reported inconsistent associations with a PSEN1 intronic polymorphism. We therefore hypothesized that linkage disequilibrium between the intronic PSEN1 polymorphism and the functional promoter polymorphism might explain the conflicting reports in LOAD. We analysed both variations in 356 LOAD patients and 230 controls in a population-based case-control study. In addition, we re-analysed all published literature on the PSEN1 intronic polymorphism in a meta-analysis. No significant association was found with the PSEN1 intronic or promoter polymorphism in our case-control sample. In the meta-analysis no major differences between patients and controls were found for the PSEN1 intronic variation. Together, our results do not support a major role for variable expression of PSEN1 in LOAD.</description>
    </item> <item>
      <title>The Cystatin C polymorphism is not associated with early-onset Alzheimer's disease. (Article)</title>
      <link>http://repub.eur.nl/res/pub/5854/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Genetic testing should not be advocated as a diagnostic tool in familial forms of dementia (Article)</title>
      <link>http://repub.eur.nl/res/pub/8495/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression (Article)</title>
      <link>http://repub.eur.nl/res/pub/9244/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Mutations in the presenilin 1 ( PSEN1 ) gene have been implicated in
      18-50% of autosomal dominant cases with early-onset Alzheimer's disease
      (EOAD). Also, PSEN1 has been suggested as a potential risk gene in
      late-onset AD cases. We recently showed genetic association in a
      population-based study of EOAD, pointing to the 5' regulatory region of
      PSEN1. In this study we systematically screened 3.5 kb of the PSEN1
      upstream region and found four novel polymorphisms. Genetic analysis
      confirmed association of two polymorphisms with increased risk for EOAD.
      In addition, we detected two different mutations in EOAD cases at-280
      and-2818 relative to the transcription initiation site in exon 1A of
      PSEN1. Analysis of the mutant and wild-type-280 variants using luciferase
      reporter gene expression in transiently transfected neuroblastoma cells
      showed a 30% decrease in transcriptional activity for the mutant-280G
      PSEN1 promoter variant compared with the wild-type variant-280C. Our data
      suggest that the increased risk for EOAD associated with PSEN1 may result
      from genetic variations in the regulatory region leading to altered
      expression levels of the PSEN1 protein.</description>
    </item> <item>
      <title>Mutation screening of the tau gene in patients with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5838/</link>
      <pubDate>1999-12-24T00:00:00Z</pubDate>
      <description>Hyperphosphorylated microtubule associated protein tau, present in neurofibrillary tangles, is a prominent pathological feature of Alzheimer's disease (AD). The gene encoding tau (MAPT) was recently found mutated in frontotemporal dementia (FTD) and other tauopathies. We studied MAPT as a candidate gene in the etiology of AD. The study population consisted of 101 early-onset AD patients and 117 controls. Mutation analysis did not detect causal mutations in exons 9 to 13 encoding the microtubule-binding domains involved in FTD, however, two novel polymorphisms were detected in exon 9. Using the Ala169 polymorphism in exon 9 and a previously reported (CA)n-repeat polymorphism in intron 9, an association study was performed. No association with early-onset AD was detected. Together, our data indicate that MAPT does not play a role in early-onset AD.</description>
    </item> <item>
      <title>The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/8491/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>